Skip the surgery and pop the placebo, writes cheeky surgeon-author

Any surgery carries risk, which is why decisions to put patients under the knife should be carefully considered. However, one surgeon is calling attention to the fact that some common procedures end up being about as effective as a placebo procedure would have been—and the placebo would have cost a lot less while doing the patient zero harm.

Australian orthopedic surgeon and professor Ian Harris, also known as “Dr. Skeptic,” makes the case in a new book titled Surgery, The Ultimate Placebo: A Surgeon Cuts through the Evidence.

With his blog as his medium, Dr. Harris has taken it upon himself to review his own book. 

The review may be somewhat tongue in cheek, but the book sounds genuinely intriguing.

 

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.